

Emergent BioSolutions Inc.  
Form 4  
November 13, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Labinger Barry

(Last) (First) (Middle)  
400 PROFESSIONAL DR, SUITE 400  
(Street)

GAITHERSBURG, MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
Emergent BioSolutions Inc. [EBS]

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/11/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
EVP, Biosciences Div.

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | (A) or (D) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|------------|---|--|--|
|                                 |                                      |  | Code                           | V   | Amount     | Price   |  |  |
| Common Stock                    | 11/11/2015                           |  | S                              |   | 6,564      | \$ 35.51<br>(4)   | D  |  |
| Common Stock (1)                | 11/11/2015                           |  | M                              |   | 9,373      | \$ 28.09  | D  |  |
| Common Stock (1)                | 11/11/2015                           |  | S                              |   | 9,373      | \$ 35.5   | D  |  |
| Common Stock (2)                | 11/11/2015                           |  | M                              |   | 10,095     | \$ 20.94  | D  |  |
| Common Stock (2)                | 11/11/2015                           |  | S                              |   | 10,095     | \$ 35.5<br>(4)  | D  |  |

Edgar Filing: Emergent BioSolutions Inc. - Form 4

|                             |            |   |        |   |          |        |   |
|-----------------------------|------------|---|--------|---|----------|--------|---|
| Common Stock <sup>(2)</sup> | 11/12/2015 | M | 10,094 | A | \$ 20.94 | 40,323 | D |
| Common Stock <sup>(2)</sup> | 11/12/2015 | S | 10,094 | D | \$ 36    | 30,229 | D |
| Common Stock <sup>(3)</sup> | 11/11/2015 | F | 1,671  | D | \$ 35.88 | 28,558 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title Amount or Number of Shares                              |
| Stock Option <sup>(1)</sup>                | \$ 28.09   | 11/11/2015                           |  | M                              | 9,373   | 03/11/2014 03/10/2021                                    | Common Stock 9,373  |
| Stock Option <sup>(2)</sup>                | \$ 20.94   | 11/11/2015                           |  | M                              | 10,095  | 11/11/2013 11/11/2020                                    | Common Stock 10,095   |
| Stock Option <sup>(2)</sup>                | \$ 20.94   | 11/12/2015                           |  | M                              | 10,094  | 11/11/2013 11/11/2020                                    | Common Stock 10,094   |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                       |       |
|--|---------------|-----------|-----------------------|-------|
|  | Director      | 10% Owner | Officer               | Other |
| Labinger Barry<br>400 PROFESSIONAL DR, SUITE 400<br>GAITHERSBURG, MD 20879 |               |           | EVP, Biosciences Div. |       |

## Signatures

/s/ Eric Burt,  
attorney-in-fact

11/13/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Consists of an option granted under the company's stock incentive plan on March 11, 2014.
- (2) Consists of an option granted under the company's stock incentive plan on November 12, 2013.
- (3) Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
- (4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.50-\$35.59, inclusive.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.